1. Home
  2. NRSN vs JFU Comparison

NRSN vs JFU Comparison

Compare NRSN & JFU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NRSN
  • JFU
  • Stock Information
  • Founded
  • NRSN 2017
  • JFU 2006
  • Country
  • NRSN Israel
  • JFU China
  • Employees
  • NRSN N/A
  • JFU N/A
  • Industry
  • NRSN Biotechnology: Pharmaceutical Preparations
  • JFU Finance: Consumer Services
  • Sector
  • NRSN Health Care
  • JFU Finance
  • Exchange
  • NRSN Nasdaq
  • JFU Nasdaq
  • Market Cap
  • NRSN 17.8M
  • JFU 17.9M
  • IPO Year
  • NRSN 2021
  • JFU 2019
  • Fundamental
  • Price
  • NRSN $1.14
  • JFU $1.52
  • Analyst Decision
  • NRSN Hold
  • JFU
  • Analyst Count
  • NRSN 1
  • JFU 0
  • Target Price
  • NRSN N/A
  • JFU N/A
  • AVG Volume (30 Days)
  • NRSN 360.5K
  • JFU 13.8K
  • Earning Date
  • NRSN 12-31-2024
  • JFU 12-27-2024
  • Dividend Yield
  • NRSN N/A
  • JFU N/A
  • EPS Growth
  • NRSN N/A
  • JFU N/A
  • EPS
  • NRSN N/A
  • JFU 0.09
  • Revenue
  • NRSN N/A
  • JFU $40,614,155.00
  • Revenue This Year
  • NRSN N/A
  • JFU N/A
  • Revenue Next Year
  • NRSN N/A
  • JFU N/A
  • P/E Ratio
  • NRSN N/A
  • JFU $16.31
  • Revenue Growth
  • NRSN N/A
  • JFU N/A
  • 52 Week Low
  • NRSN $0.51
  • JFU $1.13
  • 52 Week High
  • NRSN $2.33
  • JFU $3.85
  • Technical
  • Relative Strength Index (RSI)
  • NRSN 56.63
  • JFU 50.07
  • Support Level
  • NRSN $0.80
  • JFU $1.46
  • Resistance Level
  • NRSN $1.29
  • JFU $1.63
  • Average True Range (ATR)
  • NRSN 0.13
  • JFU 0.14
  • MACD
  • NRSN 0.01
  • JFU 0.02
  • Stochastic Oscillator
  • NRSN 68.75
  • JFU 68.52

About NRSN NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.

About JFU 9F Inc.

9F Inc is a financial account platform integrating and personalizing financial services in China. It provides a range of financial products and services across online lending, wealth management, and payment facilitation, all integrated under a single digital financial account. The company generates the majority of its revenue from Loan facilitation services. All its revenues are generated from the People's Republic of China.

Share on Social Networks: